Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May 4;8:144.
doi: 10.3389/fonc.2018.00144. eCollection 2018.

Precision Medicine in Hormone Receptor-Positive Breast Cancer

Affiliations
Free PMC article
Review

Precision Medicine in Hormone Receptor-Positive Breast Cancer

Azadeh Nasrazadani et al. Front Oncol. .
Free PMC article

Abstract

In recent decades, breast cancer has become largely manageable due to successes with hormone receptor targeting. Hormone receptor-positive tumors have favorable outcomes in comparison to estrogen receptor (ESR1, ER)/progesterone receptor-negative tumors given the targetable nature of these tumors, as well as their inherently less aggressive character. Nonetheless, treatment resistance is frequently encountered due to a variety of mechanisms, including ESR1 mutations and loss of ER expression. A new era of precision medicine utilizes a range of methodologies to allow real-time analysis of individual genomic signatures in metastases and liquid biopsies with the goal of finding clinically actionable targets. Preliminary studies have shown improved progression-free survival and overall survival with implementation of this information for clinical decision making. In this review, we will discuss the opportunities and challenges in integrating precision medicine through next-generation genomic sequencing into the management of breast cancer.

Keywords: circulating tumor DNA; circulating tumor cells; hormone receptor-positive breast cancer; liquid biopsy; personalized medicine.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. American Cancer Society. Breast Cancer Facts & Figures 2017–2018. (2017). Available from: http://www.cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures (Accessed: January 27, 2018).
    1. American Cancer Society. Cancer Facts and Figures 2017. (2017). Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf (Accessed: January 27, 2018).
    1. Quirke VM. Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation. Front Pharmacol (2017) 8:620.10.3389/fphar.2017.00620 - DOI - PMC - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med (1988) 319(26):1681–92.10.1056/NEJM198812293192601 - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group. Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 378(9793):771–84.10.1016/S0140-6736(11)60993-8 - DOI - PMC - PubMed
Feedback